Karyopharm Therapeutics (NASDAQ:KPTI) Issues Quarterly Earnings Results

Karyopharm Therapeutics (NASDAQ:KPTI) issued its quarterly earnings results on Tuesday. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.01, Zacks reports. The business had revenue of $38.78 million during the quarter, compared to the consensus estimate of $37.86 million. During the same period in the prior year, the firm earned ($0.30) earnings per share. Karyopharm Therapeutics updated its FY 2024 guidance to EPS.

Karyopharm Therapeutics Stock Performance

Karyopharm Therapeutics stock traded up $0.01 on Thursday, reaching $0.90. The company’s stock had a trading volume of 1,069,318 shares, compared to its average volume of 1,268,549. The company has a market cap of $112.21 million, a price-to-earnings ratio of -0.75 and a beta of 0.16. The business’s fifty day moving average price is $0.81 and its 200 day moving average price is $0.91. Karyopharm Therapeutics has a twelve month low of $0.62 and a twelve month high of $1.95.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on KPTI. StockNews.com lowered Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday. Piper Sandler lifted their price objective on Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Karyopharm Therapeutics in a research note on Friday, November 1st. Robert W. Baird decreased their price target on Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $3.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, August 7th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Karyopharm Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $5.00.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).